№ files_lp_4_process_3_102150
File format: docx
Character count: 2612
File size: 1298 KB
Date:
April 23, 2020
Artist:
Goody Grace
Song Title:
If I Want To
Genre:
Alternative, Pop-punk
Label:
Atlantic Records
Featured Artist:
BLINK 182
Producer(s):
Goody Grace, Jake Torrey, afterhrs
Songwriter(s):
Goody Grace, Jake Torrey
Lyric Video:
Yes
Streaming Platforms:
All DSPs and streaming services
Playlist:
"I’ll Get High If I Want To" (SPIN)
Press Contact:
Jessica Nall / [email protected], Jason Davis / [email protected], Megan Rasmussen (Tour) / [email protected]
Description:
Press release for the new single “If I Want To” by Goody Grace, a 4/20-friendly anthem that interpolates Lesley Gore’s “It’s My Party” with a modern twist, following the success of “Scumbag” featuring BLINK 182.
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2025
Region / city:
[insert local health board name]
Subject:
Pharmaceutical Service, Public Health
Document type:
Patient Group Direction (PGD)
Organ / institution:
Welsh Medicines Advice Service, NHS Wales
Author:
Dianne Burnett, National Lead Pharmacist, Medicines Advice
Target audience:
Pharmacists, Healthcare professionals
Validity period:
01 April 2025 – 31 March 2028
Approval date:
11 February 2025
Amendment date:
06 January 2025
Year:
2024-2025
Region / City:
Washington State
Topic:
Medical authorization form
Document Type:
Medical Authorization
Organization:
Washington State School for the Blind
Author:
Licensed Health Professional
Target Audience:
Parents/Guardians, School Staff
Effective Period:
07/01/2024 - 08/31/2025
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2019
Region / city:
Australia
Topic:
Medical device, eye care
Document type:
Public Summary Document
Organ / institution:
Therapeutic Goods Administration (TGA), Pharmaceutical Benefits Advisory Committee (PBAC)
Author:
Allergan Australia Pty Ltd
Target audience:
Healthcare professionals, medical practitioners
Period of validity:
Not specified
Approval date:
13 March 2019
Date of amendments:
Not specified
Note:
Date
Follow the Six Rights of Medication Administration:
Right student, Right medication, Right dose, Right time, Right route and Right documentation. Know which eye is to be treated. Initials may be used to specify the eye that requires treatment, O.D. = right eye; O.S. = left eye; O.U. = both eyes.
Topic:
Medication administration
Document Type:
Training checklist
Organization:
School
Author:
Not specified
Target Audience:
Staff administering medication
Period of validity:
School year
Year:
2019
Region / city:
Australia
Subject:
Medical Device Registration
Document Type:
Medical Application
Organization:
Seqirus (Australia) Pty Ltd
Author:
Seqirus
Target Audience:
Medical practitioners, optometrists, and healthcare professionals
Period of validity:
Not specified
Approval Date:
July 2019
Modification Date:
Not specified
Medicine:
Ciclosporin 1 mg/mL (0.1%) eye drops
Brand name:
Ikervis®
Sponsor:
Seqirus (Australia) Pty Ltd
Regulatory authority:
Therapeutic Goods Administration (TGA)
Registration date:
11 December 2020
Program:
Pharmaceutical Benefits Scheme (PBS)
Restriction type:
Authority Required (Streamlined)
Schedule category:
GENERAL – General Schedule (Code GE)
Indication:
Treatment of severe keratitis in adult patients with dry eye disease not improved despite tear substitutes
Population:
Patients aged 18 years or older with severe keratitis and dry eye disease
Comparators:
Best supportive care including preservative free artificial tears
Clinical criteria (initiation):
Corneal fluorescein staining grade 4 (modified Oxford scale or equivalent) and OSDI ≥ 23; failure of optimised preservative free tear substitutes
Clinical criteria (continuation):
Demonstrated adequate response at 6 months
Definition of adequate response:
Improvement in CFS ≥ 3 grades and ≥ 30% improvement in OSDI from baseline
Prescriber restrictions:
Ophthalmologist or optometrist
Economic basis:
Cost-utility analysis versus best supportive care
Proposed treatment phases:
Initiation; continuation; continuation after assessment of response
Year:
2026
Region / City:
N/A
Topic:
Veterinary medicine, Antibiotics
Document Type:
Instruction Manual
Author:
N/A
Target Audience:
Pet owners, Veterinarians
Expiration Period:
14 days after mixing
Approval Date:
N/A
Date of Changes:
N/A
Year:
N/A
Region / City:
N/A
Topic:
Vaccine composition
Document Type:
Supplementary Table
Author:
N/A
Target Audience:
N/A
Period of Validity:
N/A
Approval Date:
N/A
Amendment Date:
N/A
Note:
Year
Context description:
A submission for the inclusion of perfluorohexyloctane eye drops in the PBS list for severe dry eye syndrome treatment in patients sensitive to preservatives.
Year:
2023
Region / city:
Gulf
Topic:
Stock Markets, Oil Prices
Document Type:
Financial Report
Organization / Institution:
Reuters
Author:
Reuters
Target Audience:
Investors, Financial Analysts
Period of validity:
2023
Approval Date:
2023
Date of Changes:
N/A